Literature DB >> 15673788

Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.

Amy Sarah Ginsburg1, Jin Lee, Samuel C Woolwine, Jacques H Grosset, Fayez M Hamzeh, William R Bishai.   

Abstract

To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673788      PMCID： PMC547230          DOI： 10.1128/AAC.49.2.853-856.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.

Authors:  P D Lister; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

4.  In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1968-03

5.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics.

Authors:  T Murakawa; H Sakamoto; T Hirose; M Nishida
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors:  Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 7.  Fluoroquinolones, tuberculosis, and resistance.

Authors:  Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal:  Lancet Infect Dis       Date:  2003-07       Impact factor: 25.071

8.  Bactericidal activity of cephalosporins in an in vitro model simulating serum levels.

Authors:  M Nishida; T Murakawa; T Kamimura; N Okada
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

9.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors:  Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2003-10-24       Impact factor: 21.405

10.  In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.

Authors:  Chiu-Yeung Chan; Carrie Au-Yeang; Wing-Wai Yew; Chi-Chiu Leung; Augustine F B Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191
View more
  3 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 2.  In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.

Authors:  Pavan K Vaddady; Richard E Lee; Bernd Meibohm
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

3.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.